Breaking News

Financial Report: Merck 3Q

October 26, 2012

Key products help offset August Singulair patent expiry


3Q Revenues: $11.5 billion (-4%)
3Q Earnings: $1.8 billion (+2%)
YTD Revenues: $35.5 billion (-1%)
YTD Earnings: $5.4 billion (+10%)
Comments: Pharmaceutical sales were down 5% to $9.9 billion, including a 5% negative impact from foreign exchange and the loss of market exclusivity for Singulair in the U.S. in August (-55% to $602 million). Januvia sales were up 15% to $975 million. Zetia sales were up 5% to $645 million. Gardasil sales were up 31% to $581 million. Janumet and Isentress sales were up 16% to $405 and $399 million, respectively. Combined sales of Remicade and Simponi declined 9% to $576 million in the quarter. Animal Health sales were down 1% to $815 million. Consumer Care revenues were up 7% to $451 million.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments